You are here

  • Home
  • Archive
  • Volume 20, Issue 6
  • Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer

 

Online download statistics by month:

Online download statistics by month: March 2019 to May 2023

AbstractFullPdf
Mar 2019600
Apr 20191800
May 20191801
Jun 2019800
Jul 20193801
Aug 20191401
Sep 20191200
Oct 20192801
Nov 2019800
Dec 20191000
Jan 20202201
Feb 2020800
Mar 20201600
Apr 2020600
May 20202600
Jun 20202000
Jul 20201000
Aug 2020400
Sep 20202400
Oct 20201000
Nov 2020600
Dec 20201000
Jan 20211800
Feb 20212001
Mar 2021600
Apr 20211002
May 2021200
Jul 2021200
Oct 20211801
Nov 2021800
Dec 20211200
Jan 20221200
Feb 20221000
Mar 20221400
Apr 20221000
May 20223200
Jun 20223200
Jul 20222800
Aug 20226400
Sep 20223600
Oct 20225001
Nov 20222000
Dec 20221000
Jan 2023400
Feb 20237200
Mar 2023400
Apr 2023600
May 2023400
Total826010